Policy
China could ‘corner’ biopharmaceutical sector with new plan, US panel warns
BioPharma Dive · By Jonathan Gardner ·
The Brief
- A US commission warned of an overdependence on China in biopharmaceuticals.
- The commission urged US lawmakers to act quickly to prevent that overdependence.
- The commission said American patients could become vulnerable to supply chain weaponization.
Why it matters
Heavy reliance on a single foreign country for drug supply chains could expose patients and producers to disruption or political pressure, which matters for anyone tracking medicine supply and biotech policy.
Who’s affected
- patients who depend on pharmaceutical supply chains
- biopharmaceutical companies and their suppliers
- US lawmakers and policymakers
- #biopharmaceuticals
- #supply chain
- #china
- #us policy
- #drug security
- #biotech
A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”